PYGL
Basic information
Region (hg38): 14:50857891-50944483
Links
Phenotypes
GenCC
Source:
- glycogen storage disease VI (Definitive), mode of inheritance: AR
- glycogen storage disease VI (Strong), mode of inheritance: AR
- glycogen storage disease VI (Strong), mode of inheritance: AR
- glycogen storage disease VI (Strong), mode of inheritance: AR
- glycogen storage disease VI (Supportive), mode of inheritance: AR
- glycogen storage disease VI (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Glycogen storage disease VI | AR | Biochemical | The condition can include manifestations suc has hypoglycemia, ketosis, and growth retardation, and recommendations for care include laboratory-based monitoring (eg, including liver function tests, glucose, and ketones), radiological monitoring (abdominal imaging), and nutritional recommendations and avoidance of certain medications in order to help improve metabolic to control and prevent the primary complications; Specific care during pregnancy has been recommended | Biochemical | 13646331; 5904467; 9529348; 9536091; 17705025; 20301788; 21646031; 25266922; 30659246 |
ClinVar
This is a list of variants' phenotypes submitted to
- Glycogen_storage_disease,_type_VI (259 variants)
- Inborn_genetic_diseases (74 variants)
- not_provided (72 variants)
- not_specified (23 variants)
- PYGL-related_disorder (21 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PYGL gene is commonly pathogenic or not. These statistics are base on transcript: NM_000002863.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 57 | 62 | ||||
missense | 14 | 154 | 13 | 189 | ||
nonsense | 13 | 21 | ||||
start loss | 1 | 1 | ||||
frameshift | 12 | 22 | ||||
splice donor/acceptor (+/-2bp) | 11 | 18 | ||||
Total | 42 | 37 | 161 | 70 | 3 |
Highest pathogenic variant AF is 0.000145594
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PYGL | protein_coding | protein_coding | ENST00000216392 | 20 | 86846 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.71e-17 | 0.492 | 41757 | 26796 | 57195 | 125748 | 0.424 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.203 | 478 | 466 | 1.03 | 0.0000254 | 5610 |
Missense in Polyphen | 246 | 239.07 | 1.029 | 2934 | ||
Synonymous | 0.297 | 177 | 182 | 0.972 | 0.0000103 | 1601 |
Loss of Function | 1.74 | 33 | 45.7 | 0.722 | 0.00000259 | 525 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 1.31 | 1.31 |
Ashkenazi Jewish | 0.338 | 0.335 |
East Asian | 0.610 | 0.607 |
Finnish | 0.360 | 0.361 |
European (Non-Finnish) | 0.343 | 0.342 |
Middle Eastern | 0.610 | 0.607 |
South Asian | 0.446 | 0.442 |
Other | 0.408 | 0.407 |
dbNSFP
Source:
- Function
- FUNCTION: Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties.;
- Disease
- DISEASE: Glycogen storage disease 6 (GSD6) [MIM:232700]: A metabolic disorder characterized by mild to moderate hypoglycemia, mild ketosis, growth retardation, and prominent hepatomegaly. Heart and skeletal muscle are not affected. {ECO:0000269|PubMed:9529348}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Insulin resistance - Homo sapiens (human);Starch and sucrose metabolism - Homo sapiens (human);Glucagon signaling pathway - Homo sapiens (human);Necroptosis - Homo sapiens (human);Insulin signaling pathway - Homo sapiens (human);Glycogen synthetase deficiency;Glycogenosis, Type III. Cori disease, Debrancher glycogenosis;Mucopolysaccharidosis VI. Sly syndrome;Sucrase-isomaltase deficiency;Glycogenosis, Type IV. Amylopectinosis, Anderson disease;Glycogenosis, Type VI. Hers disease;Starch and Sucrose Metabolism;TNF alpha Signaling Pathway;Glycogen Metabolism;Neutrophil degranulation;Metabolism of carbohydrates;glycogenolysis;Innate Immune System;Immune System;Metabolism;Glycogen breakdown (glycogenolysis);Glycogen metabolism
(Consensus)
Recessive Scores
- pRec
- 0.423
Intolerance Scores
- loftool
- 0.0522
- rvis_EVS
- 0.21
- rvis_percentile_EVS
- 67.5
Haploinsufficiency Scores
- pHI
- 0.242
- hipred
- N
- hipred_score
- 0.492
- ghis
- 0.496
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.992
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pygl
- Phenotype
Gene ontology
- Biological process
- glycogen metabolic process;glycogen catabolic process;5-phosphoribose 1-diphosphate biosynthetic process;response to bacterium;glucose homeostasis;neutrophil degranulation;necroptotic process
- Cellular component
- extracellular region;cytoplasm;cytosol;secretory granule lumen;extracellular exosome;ficolin-1-rich granule lumen
- Molecular function
- purine nucleobase binding;protein binding;ATP binding;glucose binding;drug binding;glycogen phosphorylase activity;AMP binding;vitamin binding;pyridoxal phosphate binding;bile acid binding;protein homodimerization activity;linear malto-oligosaccharide phosphorylase activity;SHG alpha-glucan phosphorylase activity